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Abstract
Background: Systemic inflammation has long been related with adverse survival outcomes in cancer patients, and
its biomarkers, such as the Neutrophil-to-Lymphocyte Ratio (NLR), are recognized as poor prognostic indicators.
However, the role of eosinophils in this field has been largely overlooked. Here, we describe two new pre-treatment
biomarkers, expressed as Eosinophil-to-Lymphocytes Ratio (ELR) and Eosinophil*Neutrophil-to-Lymphocytes ratio
(ENLR), and we analyse their impact on prognosis of endometrial cancer (EC) patients.
Methods: A total of 163 consecutive patients diagnosed with EC and treated with postoperative radiotherapy +/−
chemotherapy in our institution from January 2011 to December 2015 were evaluated. The cohort was divided in
two groups applying the cut-off value of 0.1 and 0.5 according to ROC curve for pre-treatment ELR and ENLR,
respectively. After patients’ stratification according to the ESMO-ESGO-ESTRO modified risk assessment, subgroup
analyses were conducted.
Results: Higher values of ELR and ENLR were associated with worse OS (p= 0.004 and p= 0.010, respectively). On univariate
analysis, the factors associated with shorter OS were ELR≥ 0.1 (HR = 2.9, p= 0.017), ENLR ≥ 0.5 (HR = 3.0, p= 0.015), advanced
FIGO stage (HR = 3.4, p = 0.007), endometrioid histology (HR = 0.26, p = 0.003) and ESMO-ESGO-ESTRO high-risk
(HR = 10.2, p = 0.023). On multivariate Cox regression, higher ELR and ENLR were independently associated
with a worse outcome adjusted for the standardly applied prognostic factors.
Conclusions: Increased values of ELR and ENLR portend worse OS in EC, especially in patients classified by
the ESMO-ESGO-ESTRO guidelines as a high-risk group. To our best knowledge, this is the first report
describing eosinophils-related ratios as prognostic biomarkers in malignant tumours.
Keywords: Endometrial cancer, Systemic inflammation, Circulating eosinophils, Neutrophil-to-lymphocyte ratio (NLR),
Eosinophil-to-lymphocytes ratio (ELR), Eosinophil*neutrophil-to-lymphocytes ratio (ENLR), ESMO-ESGO-ESTRO risk
assessment, Overall survival
Background
Endometrial cancer (EC) is the 5th most common form of
female cancer in the USA, with 61,380 new cases diagnosed
in 2017, and responsible for 10,920 deaths over the same
year [1]. According to the FIGO 2009 classification, 80% of
EC are diagnosed in stages I-II, with 5-year survival rates of
89.6% in stage I, decreasing to 78.3% in stage II, 61.9% in
stage III, and 21.1% in stage IV [2]. Although EC diagnosed
in early stages is potentially curative with surgery followed
by adjuvant radiotherapy +/− chemotherapy, about 15% of
these patients present an increased risk of cancer progres-
sion [3]. This risk is assessed by the ESMO-ESGO-ESTRO
risk stratification, based on tumour characteristics [4, 5].
However, the impact of other factors, such as systemic
inflammation, is gaining importance as an indicator of
poor prognostic in cancer patients [6, 7]. The interest of
this host-dependent response, expressed through prognos-
tic ratios composed of circulating white blood cells, lies
mainly on circulating neutrophils, which have been stud-
ied as neutrophil-to-lymphocytes ratio (NLR) [8, 9]. None-
theless, the role of other subpopulations of leukocytes,
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such as eosinophils, has been largely overlooked in
tumour progression [10]. Although some reports dating
from the 1950s already suggested the role of circulating
eosinophils as a biomarker of tumour persistence or re-
currence after radiotherapy, recent studies confirm that
eosinophils act as an important modulator and effector of
both innate and adaptive immune response [11–15].
Eosinophils link two different mechanisms of host defence:
against allergens and against malignancies, as they secret
cytokines, which guide CD8 (+) T cells and enhance their
infiltration into the tumour, and induce the barrier
permeability [16–19]. Recently, a high level of blood
eosinophils was associated with better survival in metastatic
melanoma [20].
Nonetheless, their role in cancer progression remains con-
troversial as they may be considered as tumour-associated
tissue eosinophilia (TATE) or as tumour-associated blood
eosinophilia (TABE) [16, 21, 22]. Classically, TATE is more
often reported in the literature and generally considered as a
favourable prognosticator, while TABE is usually described
as a consequence of tumour necrosis in advanced disease,
hence related to poorer outcomes [23, 24]. Some authors
suggest that the release of damage-associated molecular pat-
terns (DAMPs) during tumour necrosis causes immunosup-
pression in tumour microenvironment and recruits diverse
inflammatory cells, including circulating eosinophils, which
limit the biologic activity of DAMPs [25, 26]. This mechan-
ism may clarify why TATE has been long associated with an
improved prognosis and may be the reason for the inverse
association between atopic disease and the risk of cancer
[27, 28].
The aim of the present study was to explore the im-
pact of the level of pre-treatment circulating eosinophils
and lymphocytes, expressed as ratios, on survival out-
comes in EC patients.
Methods
After the Institutional Review Board approval, a review of
our department’s database of patients with EC treated at our
institution with external beam radiotherapy (EBRT) and/or
High Dose Rate Brachytherapy (HDR-BT) in a period of five
years was conducted. All patients included signed the in-
formed consent for treatment and data processing.
Patients’ characteristics
The data of 163 patients diagnosed with histologically
confirmed EC and treated with postoperative radiotherapy
at our centre from January 2011 to December 2015 were
retrospectively reviewed. All patients underwent hysterec-
tomy as a first treatment, with laparoscopic pelvic para-
aortic lymphadenectomy in 107 cases (81.7%), and had
pre-treatment blood test results done within 3months be-
fore surgery. Patients diagnosed with acute or chronic in-
fections, including human immunodeficiency virus (HIV),
any type of immunodeficiency, other active malignancies,
haematological disorders, steroid or anti-inflammatory
treatment for any reason, were excluded. The median age
at diagnosis was 65 years (y), mean 64.79, range 41–90.
The most frequent histology was endometrioid carcinoma
(73.3%). The disease stage was classified as non-advanced
(stage I-II) in 98 patients (74.8%).
The combination of EBRT and HDR-BT was adminis-
tered to 88 patients (65.2%), with a mean dose of 53.4 Gray
(Gy) (range 21–75). Only 43 patients (32.8%) were treated
exclusively with HDR-BT (mean dose 10.0 Gy, range 7–20).
All patients were stratified into six risk groups according to
ESMO-ESGO-ESTRO anatomopathological features [4].
Patients’ characteristics are detailed in Table 1.
Follow-up results
The follow up (FU) was performed, as suggested by
ESMO guidelines, every 3–4 months for the first 2 years,
and then every 6 months for the next 3 years.
Systemic inflammation biomarkers
The level of eosinophils in pre-treatment blood tests was
analysed. We created two groups using a 0.1 cut-off ac-
cording to the best receiver operating characteristics
(ROC) curve value: patients with absolute eosinophil
count (AEC) ≥ 0.1 (n = 112) vs. AEC < 0.1 (n = 19), and
we evaluated the influence of high AEC on patients’ sur-
vival outcomes.
Afterwards, we described two new systemic inflam-
matory biomarkers, expressed as follows: Eosinophil-
to-Lymphocytes Ratio (ELR) and Eosinophil*Neutro-
phil-to-Lymphocytes Ratio (ELR multiplied by the absolute
neutrophil count, ENLR), and we analysed their impact on
overall survival (OS) and progression free survival (PFS).
Additionally, we evaluated the same ratios based on post-
treatment blood tests.
Statistical analysis
All statistical tests were two-sided and statistical signifi-
cance was defined as p < 0.05. Summarized data are pre-
sented as numbers and percentages unless otherwise stated.
The primary endpoint was OS and the secondary end-
point was PFS. Predefined subgroup analysis was conducted
based on the ESMO-ESGO-ESTRO risk stratification, which
subsequently was converted into a binary variable by creat-
ing a low (groups 1–3) and a high-risk cohort (groups 4–5).
Afterwards, the study population was subdivided into
two groups, based on the cut-offs for ELR and ENLR,
separately. Both ELR and ENLR were defined as binary
variables by finding the cut-off value from a ROC curve.
The binary variables’ balance across prognostic charac-
teristics was assessed using Chi-square test (X2 test).
Frequencies were compared using Fisher’s exact test for
categorical variables. Kaplan Meier’s curves were displayed
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Table 1 Characteristics of all patients included in the study (n = 163), comparison of these characteristics according to ELR (cut-off ≥ 0.1)
and ENLR (cut-off ≥ 0.5)
Patients’ characteristics All patients included
(n = 163, % of total)
ELR < 0.1
n = 117 (%)
ELR ≥ 0.1
n = 46 (%)
p-value* ENLR < 0.5
n = 118 (%)
ENLR ≥0.5
n = 45 (%)
p-value*
Age at diagnosis (years):
< 65 years: 74 (45.4%) 4 (73.0%) 20 (27.0) .757 53 (71.6%) 21 (28.4%) .410
≥ 65 years: 89 (54.6%) 63 (70.8%) 26 (29.2) 65 (73.0%) 24 (27.0%)
FIGO 2009 stage at diagnosis:
• IA 4 (26.0%) 34 (7.1%) 9 (0.9%) .070 33 (76.7%) 10 (23.3%) .136
• IB 54 (33.2%) 33 (61.1%) 21(38.9%) 35 64.8%) 19 (35.2%)
• II 24 (14.0%) 19 (79.2%) 5 (20.8%) 18 (75.0%) 6 (25.0%)
• IIIA 9 (5.5%) 4 (44.4%) 5 (55.6%) 5 (55.6%) 4 (44.4%)
• IIIB 0 0 0 0 0
• IIIC1 15 (9.2%) 13 (86.7%) 2 (13.3%) 14 (93.3%) 1 (6.7%)
• IIIC2 7 (4.3%) 7(100%) 0 7 (100%) 0
• IVA 9 (5.5%) 6 (66.7%) 3 (33.3%) 5 (55.6%) 4 (44.4%)
• IVB 2 (1.2%) 1 (50%) 1 (50%) 1 (50.0%) 1 (50.0%)
Patients in advanced stage (FIGO I-II vs. FIGO III-IV) (n,%):
No (FIGO I-II) 121(74.2%) 85 (70.2%) 36(29.8%) .461 85 (70.2%) 36 (29.8%) .299
Yes (FIGO III-IV) 42 (25.8%) 32 (76.2%) 10(23.8%) 33 (78.6%) 9 (21.4%)
Tumour grade (n,%):
1 36 (22.1%) 24 (66.7%) 12(33.3%) .736 26 (72.2%) 10 (27.8%) .772
2 61 (37.4%) 45 (73.8%) 16(26.2%) 46 (75.4%) 15 (24.6%)
3 66 (40.5%) 48 (72.7%) 18(27.3%) 46 (69.7%) 20 (30.3%)
Patients with tumour grade 3 vs. tumour grade 1–2 (n,%):
Grade 1–2 97 (59.5%) 66 (68.0%) 31(32.0%) .865 72 (74.2%) 25 (25.8%) .593
Grade 3 66 (40.5%) 46 (69.7%) 20(30.3%) 46 (69.7%) 20 (30.3%)
Tumour histology (n,%):
Endometrioid 119 (73%) 85 (71.4%) 34(28.6%) .305 87 (73.1%) 32 (26.9%) .424
Serous-papillary 14 (8.6%) 12 (85.7%) 2 (14.3%) 10 (71.4%) 4 (28.6%)
Clear cell 5 (3.1%) 5 (100%) 0 5 (100%) 0
Squamous 6 (3.7%) 3 (50.0%) 3 (50.0%) 3 (50.0%) 3 (50.0%)
Villoglandular 2 (1.2%) 1 (50.0%) 1 (50.0%) 1 (50.0%) 1 (50.0%)
Sarcoma (not LMS or carcinosarcoma) 2 (1.2%) 2 (100%) 0 2 (100%) 0
Leiomyosarcoma 3 (1.8%) 1 (33.3%) 2 (66.7%) 1 (33.3%) 2 (66.7%)
Carcinosarcoma 12 (7.4%) 8 (66.7%) 4 (33.3%) 9 (75.0%) 3 (25.0%)
Lymphadenectomy (n,%):
No 29 (17.8%) 19 (65.6%) 10(34.5%) .409 19 (65.5%) 10 (34.5%) .361
Yes 134 (82.2%) 98 (73.1%) 36(26.9%) 99 (73.9%) 35 (26.1%)
ESMO-ESGO-ESTRO (ESMO 2015) risk groups (n,%):
1 - Low 28 (17.2%) 21 (75.0%) 7 (25.0%) .775 21 (75.0%) 7 (25.0%) .440
2 - Intermediate 31 (19.0%) 20 (64.5%) 11(35.5%) 21 (67.7%) 10 (32.3%)
3- High-Intermediate 13 (8.0%) 9 (69.2%) 4 (30.8%) 8 (61.5%) 5 (38.5%)
4 - High 75 (46.0%) 57 (76.0%) 18(24.0%) 59 (78.7%) 16 (21.3%)
5 - Advanced 14 (8.6%) 9 (64.3%) 5 (35.7%) 8 (57.1%) 6 (42.9%)
6 - Metastatic 2 (1.2%) 1 (50.0%) 1 (50.0%) 1 (50.0%) 1 (50.0%)
Patients in high-risk groups according to ESMO-ESGO-ESTRO risk classification (n,%):
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to evaluate the prognostic value of ELR and ENLR for OS
and PFS. Survival outcomes were calculated from the date
of surgery to the event occurrence, which is progression
or cancer-related death in the case of PFS, or any death in
the case of OS. If no event occurred, patients were cen-
sored at the time they were last known to be event free.
All survival outcomes were analysed using Log rank test
(LR), Breslow test (BR) was additionally applied.
The univariate and multivariate Cox regression models
were used to assess the prognostic effect of inflammatory
biomarkers and included binary variables: ELR (≥ 0.1 vs.
< 0.1), ENLR (≥ 0.5 vs. < 0.5), age (≥ 65y vs. < 65y),
ESMO-ESGO-ESTRO high-risk (groups 4–6) vs. low-risk
(groups 1–3), high grade (grade 3 vs. grade 1–2), advanced
FIGO 2009 stage (stage III-IV vs. stage I-II), endometrioid
histology (vs. other tumour histology). All statistical ana-
lyses were performed using SPSS v. 23.
Results
Survival outcomes of the entire cohort
All survival outcomes were expressed in months. After a
median follow-up of 54.8 (range 24.6–58.4), progression
was observed in 36 patients (22.1%). There was no ex-
clusive local recurrence and only one patient developed
exclusive regional recurrence (progression in pelvic
node). Both local and regional recurrence, were observed
in 10.7% of patients (n = 14), while 17.6% (n = 23) pre-
sented distant metastasis. Median PFS for the entire co-
hort was of 23.1 (range 0.2–62.2). At the moment of
data collection, 21 deaths were reported (12.33%), 20 of
them were related to cancer (12.27%). All details con-
cerning the survival outcomes according to the
ESMO-ESGO-ESTRO risk groups are included in
Table 2.
ELR
The mean value of ELR was 0.08 (SD 0.065, range 0.0–0.31,
median 0.063). Using the cut-off of 0.1 according to the
ROC with the Area Under Curve (AUC) of 0.61, we divided
the entire cohort into two groups: ELR ≥ 0.1 (n = 46) and
ELR < 0.1 (n = 117). Patients’ characteristics of the two
comparative groups are included in Table 1.
OS in the group with ELR ≥ 0.1 was 50.7months (IC 95%
43.8–57.6) vs. 62.3months (IC 95% 59.0–65.5) in the group
with ELR < 0.1 (LR p = 0.004, X2 = 6.3; BR p = 0.026,
X2 = 4.9), HR 2.9, p = 0.017 (Fig. 1).
Eleven events were reported in the high ELR group
(23.9% of patients) vs. 10 events (8.6%) in the low ELR
group (LR: p = 0.01, X2 = 6.5; BR: p = 0.026, X2 = 4.9).
Regarding the data of the entire cohort, PFS of pa-
tients according to ELR level was not significantly differ-
ent (LR p = 0.095, BR p = 0.08). However, the number of
events was higher in patients with ELR ≥ 0.1 (14 events
vs. 22 events, which meant 30.4% vs. 18.8% patients with
progression, respectively).
ELR was not correlated with patient’s age (p= 0.90), FIGO
stage at diagnosis (p = 0.77), tumour histology (p= 0.94) or
tumour grade (p= 0.86).
ENLR
The mean value of ENLR was 0.448 (SD 0.59, range 0–5.54,
median 0.31). Using the cut-off of 0.5 (ROC curve
AUC = 0.621), we divided the entire cohort into two
groups: ENLR ≥0.5 (n = 45) and ENLR < 0.5 (n = 118).
Patients’ characteristics of the two comparative groups
are included in Table 1.
Median OS in the group with ENLR ≥ 0.5 was 49.8
months (IC 95% 43.8–55.8) vs. 61.9months (IC 95% 58.6–
65.2) in the group with ENLR < 0.5 (LR: p = 0.01, X2 =
6.6; BR: p = 0.026, X2 = 4.9, HR = 3.0, p = 0.015, Fig. 2).
Ten events were reported in the high ENLR group (which
meant 22.2% of patients) vs. 11 events (9.3%) in the low
ENLR group.
Median PFS according to ENLR level was not signifi-
cantly different (LR: p = 0.1, BR: p = 0.09).
ENLR < 0.5 was not correlated with patients’ age (p= 0.81),
FIGO stage at diagnosis (p = 0.22), tumour histology
(p = 0.63) or tumour grade (p = 0.59).
Table 1 Characteristics of all patients included in the study (n = 163), comparison of these characteristics according to ELR (cut-off ≥ 0.1)
and ENLR (cut-off ≥ 0.5) (Continued)
Patients’ characteristics All patients included
(n = 163, % of total)
ELR < 0.1
n = 117 (%)
ELR ≥ 0.1
n = 46 (%)
p-value* ENLR < 0.5
n = 118 (%)
ENLR ≥0.5
n = 45 (%)
p-value*
Low (risk group 1–3) 72 (44.2%) 47 (65.3%) 25(34.7%) .496 50 (69.4%) 22 (30.6%) .484
High (risk group 4–6) 91 (55.8%) 65 (71.4%) 26(28.6%) 68 (74.7%) 23 (25.3%)
Brachytherapy exclusive (n,%):
No 110 (67.5%) 75 (68.2%) 35(31.8%) .142 77 (70.0%) 33 (30.0%) .325
Yes 53 (32.5%) 42 (79.2%) 11(20.8%) 41 (77.4%) 12 (22.6%)
Chemotherapy (n,%):
No 104 (63.8%) 72 (69.2%) 32(30.8%) .337 71 (68.3%) 33 (31.7%) .118
Yes 59 (36.2%) 45 (76.3%) 14(23.7%) 47 (79.7%) 12 (20.3%)
* X2 test or T-student test
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ELR and ENLR as independent prognostic factors
On univariate analysis, worse OS was associated with ELR ≥
0.1 (HR= 2.9, p= 0.017), ENLR ≥ 0.5 (HR 3.0, p= 0.015),
ESMO-ESGO-ESTRO high-risk (HR= 4.7, p= 0.014),
tumour grade 3 (HR= 8.1, p= 0.001) and advanced stage
(HR= 3.4, p= 0.007), while endometrioid histology was asso-
ciated with better prognosis (HR= 0.3, p= 0.003). Age ≥ 65
years did not reach significance, p= 0.055 (Table 3). All vari-
ables included in univariate analysis were evaluated in all pa-
tients using X2 tests (Table 1, Additional file 1: Figure S1,
Additional file 2: Figure S2, Additional file 3: Figure S3,
Additional file 4: Figure S4, and Additional file 5: Figure S5).
On multivariate analysis, carried out separately for ELR
and ENLR, the impact of variables used in univariate ana-
lysis on the principal endpoint (OS) was evaluated. Three
variables reached statistical significance: ELR ≥ 0.1 (HR= 4.9,
p= 0.001), ENLR ≥0.5 (HR = 3.9, p= 0.003), and tumour
grade 3 (p= 0.003 in ELR model and p= 0.007 in ENLR
model). Age ≥ 65 was statistically significant only in ENLR
model (p= 0.043) (Table 3).
Subgroups according to ESMO-ESGO-ESTRO modified risk
assessment
According to the ESMO-ESGO-ESTRO risk classifica-
tion, all patients were allocated to six different risk
groups (Table 1). Thus, we divided the entire cohort into
two groups: low-risk (groups 1–3) and high-risk cohort
(groups 4–6).
In the high-risk cohort (n = 91), 34.6% of patients with
ELR ≥ 0.1 died and OS was of 44.9 months (IC 95%
35.9–53.9) vs. 59.6 months (54.7–64.5) in the low ELR
group with 13.8% of patients dead at the end of the
study (LR: p = 0.009, X2 = 6.8, BR: p = 0.015, X2 = 5.9,





Status of patients at the end of the study (n = 163)
Alive (no evidence of disease) Disease progression Cancer-related death Non cancer related death Total
1 27 (20.8%) 1 (8.33%) 0 0 28 (17.2%)
2 30 (23.1%) 0 0 1 (100%) 31 (19.0%)
3 11 (8.4%) 0 2 (10%) 0 13 (8.0%)
4 57 (43.8%) 7 (58.33%) 11 (55%) 0 75 (46.0%)
5 5 (3.9%) 4 (33.33) 5 (25%) 0 14 (8.6%)
6 0 0 2 (10%) 0 2 (1.2%)
Total 130 (100%) 12 (100%) 20 (100%) 1 (100%) 163 (100%)
Fig. 1 Overall survival of patients with endometrial cancer (n = 163) according to the Eosinophil-to-Lymphocytes Ratio (ELR, cut-off ≥ 0.1), p = 0.004
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Additional file 6: Figure S6). PFS was not significantly dif-
ferent between the two groups (p = 0.10).
Patients in the ENLR ≥ 0.5 cohort showed a worse OS of
45.5months (IC 95%, 36.2–54.9) vs. 59.0months in ENLR
< 0.5 (IC 95%, 54.1–64.0, LR: p = 0.020, X2 = 5.4, BR: p =
0.047, X2 = 3.9, Additional file 7: Figure S7). PFS was not
significantly different between the two groups (p = 0.18).
In the low-risk cohort (n = 72), patients with ELR ≥ 0.1
(n = 25) and patients with ENLR ≥ 0.5 (n = 22) failed to
show statistically significant differences regarding OS
and PFS.
Absolute eosinophil count (AEC)
Pre-treatment blood eosinophilia, defined as an absolute
eosinophils count ≥ 0.65 × 109/L, was detected in our
cohort only in 6 patients (4.6%), all of them alive and with
no evidence of disease progression at the moment of data
collection. The mean value of AEC was 0.1 (SD 0.13, range
0–0.8, median 0.152). There were no statistical differences
in OS (55.6 months vs. 61.35 months, p = 0.154, X2 =
2.04) nor PFS (p = 0.772, X2 = 0.08) between the
group with AEC ≥ 0.1 and the one with AEC < 0.1.
Leucocytosis, neutrophilia and NLR
Patients that presented a high level of circulating WBC
(leukocytes > 11,000 × 109/L or neutrophils > 7000 × 109/L)
or NLR ≥ 2.4 (cut-off according to ROC curve, AUC 0.516)
at cancer diagnosis did not show statistical difference in OS
compared to patients with lower levels (p= 0.51, p= 0.23
and p= 0.63, respectively).
Fig. 2 Overall survival of patients with endometrial cancer (n = 163) according to the Eosinophil*Neutrophil-to-Lymphocytes Ratio (ENLR,
cut-off ≥ 0.5), p = 0.010
Table 3 Impact of ELR and ENLR on overall survival (OS): Kaplan Meier survival analysis, univariate and multivariate Cox regression











X2 p-value HR (IC 95%) p-value HR (IC 95%) p-value HR (IC 95%) p-value
Age≥ 65 years (vs. < 65 years) 3.9 0.047 2.6 (0.98–6.7) 0.055 2.8 (1.0–8.2) 0.059 2.8 (1.03–7.8) 0.043
FIGO advanced stage III (vs. stage I-II) 8.3 0.004 3.4 (1.4–8.4) 0.007 3.1 (0.9–9.8) 0.060 2.8 (0.9–8.5) 0.065
Tumour grade 3 (vs. grade 1–2) 15.8 0.000 8.1 (2.4–27.4) 0.001 6.8 (1.9–24.7) 0.003 5.8 (1.6–21.2) 0.007
Endometroid histology (vs. other histology) 10.1 0.001 0.3 (0.1–0.63) 0.003 0.4 (0.1–1.1) 0.068 0.4 (0.14–1.2) 0.099
ESMO-ESTRO-ESGO High Risk groups 4–6 (vs. groups 1–3) 7.4 0.007 4.7 (1.4–15.8) 0.014 1.2 (0.2–6.5) 0.856 1.3 (0.2–6.9) 0.770
ELR≥ 0.1 (vs. < 0.1) 6.3 0.004 2.9 (1.2–6.8) 0.017 4.9 (1.9–12.4) 0.001 – –
ENLR ≥ 0.5 (vs. < 0.5) 6.6 0.010 3.0 (1.2–7.3) 0.015 – – 3.9 (1.6–9.8) 0.003
All entries in boldface reflect p-values < 0.05
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Discussion
Systemic inflammation is a recognised feature of cancer
progression, and inflammatory biomarkers are a key sub-
ject of research on anti-tumour response. However, the
role of eosinophils in this field has long been ignored.
Even though tumour-associated blood eosinophilia is de-
scribed in a wide range of tumours [11, 12, 27], and is eas-
ily diagnosed, this finding is not so frequent in clinical
practice, and only accounts for 1–7% of all eosinophilia’s
diagnoses [21, 29]. In accordance with these reports, we
concluded that eosinophilia at cancer diagnosis was really
infrequent in our cohort and had no impact on survival
outcome. We hypothesise that it is not eosinophils alone,
but the ratios between circulating eosinophils and lym-
phocytes, that may reflect the host’s immunosuppression
status at cancer diagnosis, and may help to achieve a more
precise risk stratification of patients diagnosed with EC.
Here, we describe new eosinophil-based prognostic ra-
tios, expressed as a relationship between different sub-
types of WBC. To our best knowledge, we are the first
to propose these ratios as prognostic biomarkers in ma-
lignant tumours and to apply inflammatory biomarkers
as a tool to refine the ESMO-ESGO-ESTRO risk stratifi-
cation in EC.
We focused our study on EC because, in spite of its
generally favourable prognosis, recent studies claim that
the survival outcomes depend on factors beyond the
classically established risk indicators [30]. Moreover, the
scientific evidence of the inflammatory biomarkers in EC
is significantly lower than in other malignancies [7–9].
Our study is based on a uniformly treated cohort that
includes patients of all FIGO stages if they underwent hys-
terectomy as a first treatment. According to the ESMO
guidelines, a complete macroscopic cytoreduction is rec-
ommended even for advanced disease, while systematic
pelvic lymphadenectomy should not be performed rou-
tinely, hence lymphadenectomy was performed only in
80% of patients in our study [4]. Most patients with EC
usually present a low recurrence risk, but in our study
55.8% of patients (n = 91) belonged to the high-risk group,
which may be explained by the reference status of our in-
stitution, where patients with high-risk factors are usually
addressed. Although distant relapses often account for
only one-third of recurrences in the literature, they were
observed in 63.9% of all relapses in our cohort [4, 30]. As
most EC relapses occur within 3 years after the primary
treatment, we considered that our median FU of 55.9
months (range 52.4–59.4) was long enough [4].
Due to the correlation between ELR and ENLR, two
multivariate analysis models were evaluated: one for
ELR ≥ 0.1 (p = 0.001, HR = 4.9, IC 95%, 1.9–12.4) and
one for ENLR ≥ 0.5 (p = 0.003, HR = 3.9, IC 95%, 1.6–
9.8). Holding the other covariates constant, higher values
of ELR and ENLR were strongly associated with an in-
creased risk of death and were independent indicators of
poorer overall survival. Contrarily, ratios based on
post-treatment blood tests had no impact on patients’
prognosis.
Similarly, pre-treatment ELR and ENLR showed an
impact on OS and PFS in the high-risk group, but not in
the low-risk group (p = 0.21 and p = 0.18, respectively),
in which a limited number of events was observed.
On univariate analysis of the entire cohort, the variable
age ≥ 65y only trended toward significance (p = 0.055)
but was maintained in multivariate analysis as a clinically
important factor, and was significantly associated with
worse OS in ENLR Cox model. In the high-risk patients
(groups 4–6), age ≥ 65y was an indicator of poor survival
(p = 0.014 in univariate analysis) and was proven to be
an independent prognostic factor in both Cox regression
models [Table 4]. By contrast, FIGO advanced stage and
endometrioid histology were not significant prognostica-
tors in the univariate analysis of high-risk patients.
ENLR was described in order to demonstrate the import-
ance of the relation between eosinophils and lymphocytes.
Subsequently, we observed that the impact on OS was con-
stant and not influenced by the neutrophil count. As both
eosinophil-based ratios have proved to be independent prog-
nostic factors for OS, while NLR has not, we concluded that
the relation between eosinophils and lymphocytes was not
Table 4 Impact of ELR and ENLR on overall survival (OS): Kaplan-Meier survival analysis, univariate and multivariate Cox regression






for ELR≥ 0.1 model
MULTIVARIATE Cox regression
for ENLR ≥0.5 model
X2 p-value HR (IC 95%) p-value HR (IC 95%) p-value HR (IC 95%) p-value
Age≥ 65 years (vs. < 65 years) 6.9 0.008 3.7 (1.3–10.5) 0.014 3.2 (1.03–10.3) 0.045 3.2 (1.1–9.7) 0.038
FIGO advanced stage III (vs. stage I-II) 2.2 0.135 2.1 (0.8–5.7) 0.143 2.6 (0.8–8.6) 0.109 2.5 (0.8–7.7) 0.104
Tumour grade 3 (vs. grade 1–2) 6.7 0.010 5.6 (1.3–24.5) 0.022 6.9 (1.5–31.6) 0.013 5.8 (1.3–26.3) 0.023
Endometroid histology (vs. other histology) 1.7 0.194 0.5 (0.2–1.4) 0.202 0.5 (0.2–1.5) 0.195 0.5 (0.2–1.6) 0.257
ELR≥ 0.1 (vs. < 0.1) 3.9 0.047 3.3 (1.3–8.7) 0.014 4.6 (1.7–12.5) 0.002 – –
ENLR ≥0.5 (vs. < 0.5) 5.4 0.020 3.0 (1.1–7.7) 0.026 – – 3.9 (1.6–9.8) 0.011
All entries in boldface reflect p-values < 0.05
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affected by the presence of neutrophils, which may be inter-
preted as a superiority of eosinophil-based ratios over NLR
and Platelet-to-Lymphocytes Ratio (PLR) (Additional file 8:
Figure S8).
Our study presents some limitations, being a retrospect-
ive single institution cohort with a relatively small number
of patients, which may produce potential confounding
biases. However, almost all studies that deal with systemic
inflammation biomarkers are of retrospective nature [7–9,
29, 30]. Confirming the cut-off points for ELR and ENLR
in a larger cohort, preferably in a multicentre study, would
be important for any future investigation.
In our opinion, the most important potential bias in the
application of the biomarkers of systemic inflammation in
clinical practice is the short life span of the WBC in sys-
temic circulation. Consequently, it is difficult to com-
pletely rule out a potential influence of some temporary
acute immunological changes, such as asymptomatic in-
fections, on the systemic inflammatory response.
We are convinced that our investigation may contrib-
ute to a new stratification of EC and to further immuno-
therapy research that aim at the eosinophilic-mediate
anti-tumour response.
Conclusions
Our study presents a new concept of the role of eosino-
phils in cancer progression that may be used as a novel
prognostic tool for EC stratification. Increased values of
eosinophil-related ratios based on pre-treatment blood
tests are associated with worse OS in all EC patients and
in high-risk patients of the ESMO-ESGO-ESTRO modi-
fied risk assessment. Impact of ELR and ENLR on PFS did
not achieve statistical significance.
According to these results, the described ratios are of
interest for EC prognosis and should be considered in
the pre-treatment analysis. To our best knowledge, this
is the first report that describes and analyses
eosinophil-related ratios as prognostic indicators in can-
cer patients.
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